SYRE
Spyre Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$88.98
+1.98%Margins
Gross margin
0.0%
EBITDA margin
-205.0%
EBIT margin
-222.5%
Net margin
-197.7%
FCF margin
-230.9%
-16.2%
Return on equity
-15.3%
Return on assets
-18.3%
Return on invested capital
0.09x
Asset turnover
-$208.9M
Cash from operations
$13
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026